Senator Elizabeth Warren introduced a bipartisan bill in June 2018 (S.3032) that would exempt most marijuana-related activities from the Controlled Substances Act when they are allowed under state or tribal law.
Depression is common in patients with axSpA and is associated with more severe disease activity and functional impairment.
These data suggest that marijuana use, particularly non-medical use, is associated with poorer depression and anxiety outcomes in psychiatric patients.
These data suggest a neurologic basis for the relationship between sleep quality and depressive symptoms, even among patients with no clinical diagnosis of depression.
One of the main reasons for the frequent misdiagnosis of catatonia is the continuing misconception that it is synonymous with schizophrenia.
The rate of suicide attempts in participants assigned to intervention plus treatment as usual was half of that in participants in the treatment as usual-alone group.
Marijuana usage is increasing in adolescents, and the rate of comorbidity with mood and anxiety disorders is high. These findings may aid in identifying adolescents who are potentially at risk.
Depression is associated with poorer outcomes in ACS and these findings suggest that this course of treatment may improve long-term major adverse cardiac event outcomes.
Investigators examined traits which may predispose to violence in patients with schizophrenia, including psychopathic and impulsive traits along with aggression traits.